Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adicet Bio, Inc.
< Previous
1
2
Next >
Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
October 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
October 04, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 09, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Announces Appointment of Katie Peng to the Board of Directors
July 11, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
June 26, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference
June 01, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 18, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference
May 09, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates
May 09, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 28, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference
April 13, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 15, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
March 09, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 28, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference
February 01, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 10, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 02, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.